Abstract:Background and Objectives Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease with an increasing global burden. Available treatments for ALS present marginal efficacy. To identify novel candidate therapeutic targets for ALS, we conducted a proteome-wide Mendelian randomization (MR) study. Methods We leveraged data from the largest summary statistics for ALS to date (27,205 patients with ALS and 110,881 controls). Genetic instruments of more than 4,000 proteins defined by cis -protein quantitative loci (pQTL) genetic instruments on plasma and cerebrospinal fluid (CSF) were obtained from Fenland (discovery, n=10,709), deCODE (replication, n=35,559), and a recently published dataset (replication, n=971). To investigate the causal ALS-associated proteins, proteome-wide Mendelian randomization based on summary-data-based MR (SMR and multi-SNP-based SMR) were performed. Then, two-sample MR analyses using five additional methods were conducted as sensitivity analyses. To further address the linkage disequilibrium bias, heterogeneity in dependent instruments test and colocalization analyses were performed. Steiger filtering and bi-directional MR analyses were conducted to address the potential reverse causality. Four drug target datasets were searched to extract druggability profiles for candidate target proteins. In addition, we carried out a case-control study involving up to 21 patients with ALS and 21 matched controls to assess the protein levels difference in CSF for evidence triangulation. Results Genetically predicted levels of six circulating proteins were associated with incident ALS in primary SMR analysis. After removing proteins with any linkage disequilibrium bias , SHBG , SIGLEC7, and SIGLEC9 presented consistent associations with ALS risk, supported by medium-to-high colocalization across both plasma pQTL datasets. In CSF, higher level of SHBG was also causally associated with the risk of ALS. There was no reverse causality detected. The case-control study using CSF proteomics conducted in our center observed consistent alteration in the levels of SHBG and SIGLEC7 with MR prediction, further suggesting their functionally relevant to ALS as potential druggable targets. Discussion Combined with the findings from MR and our observational study, we prioritize SHBG , SIGLEC7, and SIGLEC9 as drug candidate proteins for ALS, and further studies are needed to verify our findings and elucidate the underlying mechanism. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by the grant (81671245) to Zhi-Ying Wu from the National Natural Science Foundation of China and the Fundamental Research Funds for the Central Universities (2019XZZX001-01-04). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committee of the Second Affiliated Hospital gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data used in Mendelian randomization study are available from referenced datasets listed in eTable 1 . Data from the proteomics study are available upon reasonable request. * ALS : Amyotrophic lateral sclerosis ATF6B : activating transcription factor 6 Beta CSF : cerebrospinal fluid CI : confidence interval CNS : central nervous system FDR : False discovery rate HEIDI : heterogeneity in dependent instruments HDGFRP3 : Hepatoma-derived growth factor-related protein IVW : inverse variance weighted GWAS : genome-wide association study LD : Linkage disequilibrium MR : Mendelian randomization NME4 : Nucleoside Diphosphate Kinase 4 pQTL : protein quantitative loci SHBG : sex hormone binding globulin SIGLEC7 : sialic acid binding lg like lectin 7 SIGLEC9 : sialic acid binding lg like lectin 9 SMR : summary data-based Mendelian randomization SOD1 : superoxide dismutase 1 SD : standard deviation TMT : Tandem Mass Tag TDP-43 : TAR DNA-binding protein 43 TPP1 : Tripeptidyl Peptidase 1

TBK1, a Prioritized Drug Repurposing Target for Amyotrophic Lateral Sclerosis: Evidence from Druggable Genome Mendelian Randomization and Pharmacological Verification in Vitro

Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Network medicine informed multi-omics integration identifies drug targets and repurposable medicines for Amyotrophic Lateral Sclerosis

Harnessing transcriptomic signals for amyotrophic lateral sclerosis to identify novel drugs and enhance risk prediction

Analyzing the ER stress response in ALS patient derived motor neurons identifies druggable neuroprotective targets

Identification of potential drug targets for amyotrophic lateral sclerosis by Mendelian randomization analysis based on brain and plasma proteomics

Prioritization of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using Protein-Wide Mendelian Randomization Analysis

Drug Repositioning Targeting Glutaminase Reveals Drug Candidates for the Treatment of Alzheimer’s Disease Patients

Unveiling therapeutic biomarkers and druggable targets in ALS: An integrative microarray analysis, molecular docking, and structural dynamic studies

A new potential therapeutic approach for ALS: A case report with NGS analysis

An ALS Therapeutic Assembly Modulator Target in Peripheral Blood Mononuclear Cells: Implications for ALS Pathophysiology, Therapeutics, and Diagnostics

Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies

A combinatorial approach to ALS therapies in the PrP.TDP43-315 model of ALS; complications and tribulations

Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis

Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization

New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022

Screens in aging-relevant human ALS-motor neurons identify MAP4Ks as therapeutic targets for the disease

Emerging targets in amyotrophic lateral sclerosis (ALS): The promise of ATP-binding cassette (ABC) transporter modulation

An Updated Evolutionary and Structural Study of TBK1 Reveals Highly Conserved Motifs as Potential Pharmacological Targets in Neurodegenerative Diseases

Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis